LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Commentary

Clinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis

Conradie F, Meintjes GA, Hughes J, Maartens G, Ferreira H, Siwendu S, Master I, Ndjeka N
Download
Download
Abstract
While clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme
Countries
South Africa
Subject Area
antibiotic resistancetuberculosisantimicrobial resistanceaccess to health care
DOI
10.7196/samj.7263
Published Date
01-Mar-2014
Languages
English
Journal
South African Medical Journal
Volume / Issue / Pages
Volume 104, Issue 3
Issue Date
06-Feb-2014
Dimensions Badge